Earnings call transcript: FluoGuide advances U.S. cancer trial setup in H1 2026

FluoGuide, a clinical-stage biotech company specializing in cancer visualization during surgery, reported a net loss of DKK 24.6 million for H1 2026 in its earnings call transcript. Despite the financial loss, the company secured FDA approval for its first U.S. site in a high-grade glioma registration trial and gained Fast Track status for the program, placing it among seven other sites nearing activation. The FDA also granted Fast Track designation for the glioma program.

The company's cash and securities amounted to DKK 50 million as of June 30, 2026, with expected tax credits totaling DKK 11 million. External operating costs stood at DKK 18.3 million, research and development expenses at DKK 13.2 million, administrative and sales and marketing costs at DKK 5.1 million, staff costs at DKK 9.7 million, and finance costs at DKK 1.6 million. FluoGuide is focused on three main goals: regulatory approval, compatibility with standard surgical equipment, and commercial viability.